A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP
Sponsor: TaiGen Biotechnology Co., Ltd.
A PHASE3 clinical study on Community-acquired Pneumonia, this trial is completed. The trial is conducted by TaiGen Biotechnology Co., Ltd. and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TaiGen Biotechnology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Chang-hua, Taiwan , Changsha, China , Chiayi City, Taiwan , Chongqing, China , Guangxi, China , Guangzhou, China , Guilin, China , Haikou, China and 27 more locations